{"commentary":{"count":47,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":19,"podcast":15,"youtube":13},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04810078\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CheckMate-67T","nct_id":"NCT04810078","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-67t-nct04810078. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CheckMate-67T","arms":[{"description":null,"label":"Arm A","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Arm C","type":"EXPERIMENTAL"},{"description":null,"label":"Arm D","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-10","type":"ESTIMATED"},"conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":681,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab and rHuPH20","type":"BIOLOGICAL"},{"name":"Nivolumab","type":"BIOLOGICAL"}],"last_update":"2026-09-22","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale","timeFrame":"Pre-dose (Day 1 to Day 28)"},{"measure":"Adjusted Geometric Mean of Nivolumab Trough Serum Concentration at Steady State (Cminss) on Original Scale","timeFrame":"Pre-dose (Day 1 to Day 28)"}],"references":[{"citation":"Albiges L, Bourlon MT, Chacon M, Cutuli HJ, Chuken YAL, Zurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15.","pmid":"39288844","type":"DERIVED"}],"start_date":{"date":"2021-05-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread","url":"https://clinicaltrials.gov/study/NCT04810078"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-67t-nct04810078"}